68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Summary

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

Timeline

Start

2022-02-15

Primary completion

2027-08-31

Completion

2028-08-31

Drugs

Indications